Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by Stylesson Oct 29, 2013 11:27am

96 Views

Post# 21858011

RE:RE:RE:"i haven't been wrong yet", Styless just cant stop lying

know the risks of one drug companies. There's a reson why this stock has little to no fundamental holders on its shareholder registry. This is a stock for retail and traders.

Too much risk in a one drug company. I like how DND has cash on the books, but that's not enough for a buy and hold strategy. Got to buy on the dips and sell into rallies. I'll be selling my sub 7 shares i just bought at 7.50.

Bullboard Posts

Covalon Technologies posts third profitable quarter in a row